Teva Hosts UK and Israeli Prime Ministers at UK-Israel Innovation Event – Announce Collaboration on New National Clinical Drug

  Teva Hosts UK and Israeli Prime Ministers at UK-Israel Innovation Event –
  Announce Collaboration on New National Clinical Drug Development Initiative
  and Dementia Research

  *Teva to collaborate on new UK Government-led clinical drug development
  *The initiative creates a single point of entry into the UK health system
    reducing complexity and increasing speed, efficiency of running drug
    development programs
  *Teva plans to invest approximately $20 million in clinical development in
    the UK and up to an additional $1 million for basic research into dementia
    – one of the critical global healthcare issues facing society today

Business Wire

JERUSALEM -- March 13, 2014

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced today a significant
collaboration between Teva and the United Kingdom (UK) Government’s National
Health Service National Institute for Health Research (NIHR) Office for
Clinical Research Infrastructure (NOCRI).

Erez Vigodman, Teva Pharmaceutical President & CEO; David Cameron, UK Prime
Minister & Binyamin Neta ...

Erez Vigodman, Teva Pharmaceutical President & CEO; David Cameron, UK Prime
Minister & Binyamin Netanyahu, Israel Prime Minister. Photo credit to Sivan

The two-part collaboration follows the creation of an important new research
infrastructure model by the UK’s National Health Service (NHS), and was
announced in the presence of UK Prime Minister, David Cameron, Israel Prime
Minister, Binyamin Netanyahu, and Teva’s President and CEO Erez Vigodman by
Dr. Michael Hayden, Teva’s President of Global R&D and Chief Scientific
Officer, at a special UK-Israel Tech Hub at the British Embassy Israel event
held at Teva’s Jerusalem site.

Clinical Drug Development Collaboration

The UK is a well-established world-leader in high quality clinical research.
However, recognizing the need to constantly innovate and improve, NOCRI has
created a novel model that streamlines the approach to undertaking clinical
development in the UK. The new model provides a single point of entry into the
UK healthcare system that cuts out the inherent complexities and
inefficiencies of dealing with many and varied stakeholders within the
combined medical and academic network on an individual and centre by centre

Teva has an extensive clinical stage pipeline that is being developed globally
and as part of this collaboration plans to spend approximately $20 million on
conducting trials in the UK. This agreement enables Teva to benefit from the
NIHR's new translational research infrastructure, their ability to set-up and
deliver studies, and access to well characterized cohorts of patients from
within the National Health Service.

Dementia Research Collaboration

The global cost of managing dementia currently exceeds $604 billion per year –
approximately equivalent to the total GDP of Switzerland. According to the
World Health Organization (WHO), the number of people living with dementia is
set to treble, to 115 million, in less than 40 years. The recent G8 Dementia
Summit in London, spearheaded by David Cameron, and attended by Dr. Hayden,
has set out to tackle the issue of dementia, and Teva has now committed to a
three-year dementia research program, providing funding of up to $1 million
for early stage work in UK academic and medical centres. This work will be
focused on understanding targets, mechanisms and new approaches to treatment
of different causes and types of dementia. As part of the agreement, NOCRI
will facilitate Teva’s access to the NIHR Biomedical Research Centres and
Units in Dementia and Translational Research Partnership in Dementia. Teva
will maintain the right to negotiate licenses to these targets.

“We are delighted to collaborate with NIHR on both clinical development and
early dementia research. It will be a catalyst for innovation to take place
within a healthcare system that is admired the world over,” said Dr. Michael
Hayden. “The relationship between Teva, Israel and the UK is a long and
fruitful one and I am proud that we can now add another example of us working
together as partners for innovation and health.”

Prime Minister Cameron said: "This is an excellent area for Britain and Israel
to collaborate on. The meaning of Teva is nature, and it is in the nature of
Israelis and Brits to be entrepreneurial. Success in technology, innovation,
and the pharmaceutical and healthcare industries and are a must if Israel and
Britain are to compete in the global race."

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global
pharmaceutical company, committed to increasing access to high-quality
healthcare by developing, producing and marketing affordable generic drugs as
well as innovative and specialty pharmaceuticals and active pharmaceutical
ingredients. Headquartered in Israel, Teva is the world's leading generic drug
maker, with a global product portfolio of more than 1,000 molecules and a
direct presence in approximately 60 countries. Teva's Specialty Medicines
businesses focus on CNS, respiratory oncology, pain, and women's health
therapeutic areas as well as biologics. Teva currently employs approximately
45,000 people around the world and reached $20.3 billion in net revenues in

Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act
of 1995:

This release contains forward-looking statements, which are based on
management’s current beliefs and expectations. Such statements involve a
number of known and unknown risks and uncertainties that could cause our
future results, performance or achievements to differ significantly from the
results, performance or achievements expressed or implied by such
forward-looking statements. Important factors that could cause or contribute
to such differences include risks relating to: our ability to develop and
commercialize additional pharmaceutical products; competition for our
innovative products, especially Copaxone^® (including competition from
orally-administered alternatives, as well as from potential generic versions);
the possibility of material fines, penalties and other sanctions and other
adverse consequences arising out of our ongoing FCPA investigations and
related matters; our ability to achieve expected results from the research and
development efforts invested in our pipeline of specialty and other products;
our ability to reduce operating expenses to the extent and during the
timeframe intended by our cost reduction program; our ability to successfully
pursue and consummate suitable acquisitions or licensing opportunities; the
extent to which any manufacturing or quality control problems damage our
reputation for quality production and require costly remediation; our
potential exposure to product liability claims that are not covered by
insurance; increased government scrutiny in both the U.S. and Europe of our
patent settlement agreements; our exposure to currency fluctuations and
restrictions as well as credit risks; the effectiveness of our patents and
other measures to protect the intellectual property rights  of our specialty
medicines;  the effects of reforms in healthcare regulation and pharmaceutical
pricing, reimbursement and coverage; governmental investigations into sales
and marketing practices, particularly for our specialty pharmaceutical
products; uncertainties related to our recent management changes;  the effects
of increased leverage and our resulting reliance on access to the capital
markets; any failure to recruit or retain executives or other key personnel;
adverse effects of political or economical instability, major hostilities or
acts of terrorism on our significant worldwide operations; interruptions in
our supply chain or problems with internal or third-party information
technology systems that adversely affect our complex manufacturing processes;
significant disruptions of our information technology systems or breaches of
our data security;  competition for our generic products, both from other
pharmaceutical companies and as a result of increased governmental pricing
pressures; competition for our specialty pharmaceutical businesses from
companies with greater resources and capabilities; decreased opportunities to
obtain U.S. market exclusivity for significant new generic products; potential
liability for sales of generic products prior to a final resolution of
outstanding patent litigation; any failures to comply with complex Medicare
and Medicaid reporting and payment obligations; the impact of continuing
consolidation of our distributors and customers; significant impairment
charges relating to intangible assets and goodwill; the potential for
significant tax liabilities; the effect on our overall effective tax rate of
the termination or expiration of governmental programs or tax benefits, or of
a change in our business; variations in patent laws that may adversely affect
our ability to manufacture our products in the most efficient manner;
environmental risks; and other factors that are discussed in our Annual Report
on Form 20-F for the year ended December 31, 2013 and in our other filings
with the U.S. Securities and Exchange Commission. Forward-looking statements
speak only as of the date on which they are made and we assume no obligation
to update or revise any forward-looking statement, whether as a result of new
information, future events or otherwise.

Photos/Multimedia Gallery Available:



Teva Pharmaceutical Industries Ltd.
Kevin C. Mannix
United States
Ran Meir
United States
Tomer Amitai
972 (3) 926-7656
Iris Beck Codner
972 (3) 926-7687
Denise Bradley
United States
Press spacebar to pause and continue. Press esc to stop.